Abstracts tagged "ANCA"

Abstract Number: 2743 • 2018 ACR/ARHP Annual Meeting
Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation
Yusuke Miyazaki¹, Shingo Nakayamada¹, Satoshi Kubo¹, Kazuhisa Nakano¹, Shigeru Iwata², Shunsuke Fukuyo³, Akio Kawabe⁴ and Yoshiya Tanaka⁵, ¹First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Fukuoka, Japan, ⁴University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, ⁵University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: B cell depletion by rituximab (RTX)is effective treatment for ANCA-associated vasculitis (AAV). However, the phenotype of peripheral B cells and the selection criteria for…
Abstract Number: 1751 • 2018 ACR/ARHP Annual Meeting
Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor
Thibault Maillet¹, Tiphaine Goletto², Guillaume Beltramo³, Henry Dupuy⁴, Stéphane Jouneau⁵, Raphaël Borie⁶, Bruno Crestani⁶, Vincent Cottin⁷, Daniel Blockmans⁸, Estibaliz Lazaro⁴, Jean-Marc Naccache⁹, Grégory Pugnet¹⁰, Hilario Nunes¹¹, Mathilde De Menthon¹², Hervé Devilliers¹³, Philippe Bonniaud³, Xavier Puéchal¹⁴, Luc Mouthon¹⁴, Bernard Bonnotte¹, Loïc Guillevin¹⁵, Benjamin Terrier¹⁴ and Maxime Samson¹, ¹Service de Médecine Interne et Immunologie Clinique, CHU de Dijon, Dijon, France, ²Service de Pneumologie, Hôpital Saint-Louis, APHP, Paris, France, ³Service de Pneumologie, CHU de Dijon, Dijon, France, ⁴Service de Médecine Interne et Maladies Infectieuses, Hôpital Haut-Lévêque, Bordeaux, France, ⁵Service de Pneumologie, CHU de Rennes; IRSET UMR 1085, Université de Rennes 1, Rennes, France, ⁶Service de Pneumologie, Hôpital Bichat, APHP, Paris, France, ⁷Service de Pneumologie, Hôpital Louis-Pradel, Bron, France, ⁸Rheumatology, UZ Leuven, Leuven, Belgium, ⁹Service de Pneumologie, Hôpital Tenon, APHP, Paris, France, ¹⁰Service de Médecine Interne, CHU de Toulouse, Toulouse, France, ¹¹Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ¹²Service de Médecine Interne, Hôpital Bicêtre, APHP, Le Kremlin-Bicêtre, France, ¹³Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹⁴Centre de Référence des Maladies Auto-immunes et Systémiques Rares, Vascularites Nécrosantes et Sclérodermie Systémique, Service de Médecine Interne, Hôpital Cochin, APHP, INSERM U1016, Université Paris Descartes, Paris, France, ¹⁵Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Interstitial lung disease (ILD), rarely described in ANCA-associated vasculitis (AAV) patients, was mainly associated with anti-MPO ANCA. ILD’s prognostic value remains unclear. This study…
Abstract Number: 2719 • 2018 ACR/ARHP Annual Meeting
Tracking the Risk of Infections in ANCA-Associated Vasculitis: Results from a Scottish Matched-Cohort Study
Shifa Sarica¹, Neeraj Dhaun², Jan Sznajd³, John Harvie³, Nicola Joss³, John McLaren⁴, Lucy McGeoch⁵, Nicole Amft⁶, Vinod Kumar⁷, Angharad Marks¹, Corri Black¹ and Neil Basu¹, ¹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom, ²University/British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, ³Department of Rheumatology, Raigmore Hospital, Inverness, United Kingdom, ⁴Fife Rheumatic Diseases Unit, Whyteman's Brae Hospital, Kirkcaldy, United Kingdom, ⁵Center for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom, ⁶Department of Rheumatology, Western General Hospital, Edinburgh, United Kingdom, ⁷Rheumatology Department, Ninewells Hospital, Dundee, United Kingdom
Background/Purpose: Evaluation of infection risk in ANCA-associated vasculitis (AAV) has been limited to small, selected populations and/or serious episodes. In this large study, we aimed…
Abstract Number: 2788 • 2018 ACR/ARHP Annual Meeting
The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated Vasculitis
Michael Walsh¹, Peter A. Merkel² and David Jayne³, ¹Nephrology, McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: It is uncertain whether plasma exchange improves clinical outcomes in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Also uncertain is whether, compared to standard therapy with…
Abstract Number: 18L • 2017 ACR/ARHP Annual Meeting
Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
Rona Smith¹, Rachel Jones², Ulrich Specks³, Carol A McAlear⁴, Kim Mynard², Simon Bond², David Jayne⁵ and Peter A. Merkel⁶, ¹Department of Medicine, University of Cambridge, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ³Mayo Clinic College of Medicine, Rochester, MN, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Background/Purpose: RITAZAREM (ClinicalTrials.gov: NCT01697267) is an international, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy after induction of remission with rituximab and glucocorticoids…
Abstract Number: 1758 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients
Xavier Puéchal¹, Christian Pagnoux², Elodie Perrodeau³, Mohamed Hamidou⁴, Jean-Jacques Boffa⁵, Xavier Kyndt⁶, François Lifermann⁷, Thomas Papo⁸, Dominique Merrien⁹, Amar Smail¹⁰, Philippe Delaval¹¹, Catherine Hanrotel-Saliou¹², Bernard Imbert¹³, Chahéra Khouatra¹⁴, Marc Lambert¹⁵, Charles Leské¹⁶, Kim H. Ly¹⁷, Edouard Pertuiset¹⁸, Pascal Roblot¹⁹, Marc Ruivard²⁰, Jean-François Subra²¹, Jean-Francois Viallard²², Benjamin Terrier²³, Pascal Cohen²³, Luc Mouthon²⁴, Philippe Ravaud³ and Loïc Guillevin for the French Vasculitis Study Group²⁵, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Paris Hotel Dieu, Paris, France, ⁴Medecine Interne, CHU Hôtel Dieu, Nantes, France, ⁵Paris Tenon, Paris, France, ⁶Valenciennes, Valenciennes, France, ⁷Dax, Dax, France, ⁸Paris Bichat, Paris, France, ⁹Compiègne, Compiègne, France, ¹⁰Amiens, Amiens, France, ¹¹Rennes, Rennes, France, ¹²Brest, Brest, France, ¹³Grenoble, Grenoble, France, ¹⁴Lyon, Lyon, France, ¹⁵Lille, Lille, France, ¹⁶Cholet, Cholet, France, ¹⁷Limoges, Limoges, France, ¹⁸Pontoise, Pontoise, France, ¹⁹Poitiers, Poitiers, France, ²⁰CHU Estaing, Department of Internal Medicine, Clermont-Ferrand, France, Clermont Ferrand, France, ²¹Angers, Angers, France, ²²Bordeaux, Bordeaux, France, ²³Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ²⁴Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France, ²⁵Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France
Background/Purpose: Adverse events, rather than active vasculitis, are the greatest threat to patients with ANCA-associated vasculitides (AAVs) during the first year of therapy but long-term…
Abstract Number: 1849 • 2017 ACR/ARHP Annual Meeting
Urinary Epidermal Growth Factor and Monocyte Chemoattractant Protein-1 As Biomarkers of Renal Involvement in ANCA-Associated Vasculitis
Catherine E. Najem¹, Wenjun Ju², Viji Nair², David Cuthbertson³, Rennie L. Rhee¹, Laura Mariani⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux⁵, Philip Seo¹², Ulrich Specks¹³, Antoine G. Sreih¹, Steven R. Ytterberg¹⁴, Jeffrey Krischer¹⁵, Matthias Kretzler⁴ and Peter A. Merkel¹⁶, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Michigan, Ann Arbor, MI, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Boston University School of Medicine, Boston, MA, ¹¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹²Medicine, Johns Hopkins University, Baltimore, MD, ¹³Mayo Clinic College of Medicine, Rochester, MN, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵University of South Florida, Tampa, FL, ¹⁶Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose :Epidermal growth factor (EGF) mediates distal tubular epithelial cell function and regeneration. Monocyte chemoattractant protein-1 (MCP-1) participates in recruitment of leukocytes to areas of…
Abstract Number: 1759 • 2017 ACR/ARHP Annual Meeting
Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Annalisa Montante¹, Alicia Le Bras², Benjamin Terrier³, Pascal Cohen³, Xavier Puéchal⁴, Alexandre Karras⁵, Philippe Ravaud⁶, Loïc Guillevin⁷ and Isabelle Durand-Zaleski⁸, ¹UNITÉ DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ²UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE PARIS DESCARTES, PARIS, France, ³Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁵Nephrology, HEGP, Paris, France, ⁶Hôpital Hôtel Dieu, Paris, France, ⁷Internal medicine, Cochin University Hospital, paris, France, ⁸UNITE DE RECHERCHE ECONOMIQUE, UNIVERSITE DE PARIS-CRETEIL, PARIS, France
Background/Purpose: Rituximab was proven to be superior to azathioprine as maintenance therapy for ANCA-associated vasculitides (AAVs) at month 28 of MAINRITSAN-1–trial follow-up. Because of rituximab’s…
Abstract Number: 2736 • 2017 ACR/ARHP Annual Meeting
Long-Term Survival in Systemic Necrotizing Vasculitides
Sabine Jardel¹, Xavier Puéchal², Alain Le Quellec³, Matthieu Groh², Mohamed Hamidou⁴, Francois Maurier⁵, Olivier Aumaître⁶, Achille Aouba⁷, Thomas Quémeneur⁸, Jean-François Subra⁹, Vincent Cottin¹⁰, Pascal Godmer¹¹, Patrice Cacoub¹², Philippe Delaval¹³, Anne-Laure Fauchais¹⁴, Eric Hachulla¹⁵, Delphine Maucort-Boulch¹⁶, Loïc Guillevin² and Jean-Christophe Lega¹⁷, ¹Lyon 1 University, Lyon, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Montpellier, Montpellier, France, ⁴Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁵Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Department of Internal Medicine, Caen University Hospital, Caen, France, ⁸Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ⁹Angers, Angers, France, ¹⁰Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, ¹¹Medecine Interne, CH Vannes, Vannes, France, ¹²Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ¹³Rennes, Rennes, France, ¹⁴Internal Medicine, Internal Medicine, Limoges, France, ¹⁵CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ¹⁶Biostatistics and bioinformatics, Centre Hospitalier Lyon Sud - Claude Bernard University Lyon 1, Lyon, France, ¹⁷Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France
Background/Purpose: The aim of the study was to describe the evolution of mortality over recent decades in systemic necrotizing vasculitides, including polyarteritis nodosa (PAN), granulomatosis…
Abstract Number: 1762 • 2017 ACR/ARHP Annual Meeting
Association of ETS1 Polymorphism in 3’ Untranslated Region with Susceptibility to Granulomatosis with Polyangiitis and Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Aya Kawasaki¹, Keita Yamashita², Fumio Hirano³, Ken-ei Sada⁴, Daisuke Tsukui⁵, Yuya Kondo⁶, Yoshitaka Kimura⁵, Kurumi Asako⁵, Shigeto Kobayashi⁷, Hidehiro Yamada⁸, Hiroshi Furukawa¹, Kenji Nagasaka⁹, Takahiko Sugihara¹⁰, Kunihiro Yamagata¹¹, Takayuki Sumida⁶, Shigeto Tohma¹², Hajime Kono⁵, Shoichi Ozaki⁸, Seiichi Matsuo¹³, Hiroshi Hashimoto¹⁴, Hirofumi Makino¹⁵, Yoshihiro Arimura¹⁶, Masayoshi Harigai¹⁷ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ²Molecular and Genetic Epidemiology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ³Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁵Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ⁶Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁷Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁸Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁹Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹⁰Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹¹Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ¹²Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹³Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹⁴Juntendo University School of Medicine, Tokyo, Japan, ¹⁵Okayama University Hospital, Okayama, Japan, ¹⁶First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁷Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: ETS Proto-oncogene 1, transcription factor (ETS1) is a transcription factor involved in immune responses. Genome-wide association studies on systemic lupus erythematosus (SLE) in Chinese…
Abstract Number: 2754 • 2017 ACR/ARHP Annual Meeting
Comparison of Individually Tailored Vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Elodie Perrodeau³, Pascal Cohen², Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Xavier Puéchal²⁰, Philippe Ravaud²¹, Luc Mouthon²² and Loïc Guillevin²⁰, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³Brest, Brest, France, ¹⁴Medecine Interne, CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, ²⁰National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²¹Hôpital Hôtel Dieu, Paris, France, ²²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission was obtained, rituximab (RTX) superiority to azathioprine (AZA) to maintain remission was shown.1 In that study, at month 28,…
Abstract Number: 797 • 2017 ACR/ARHP Annual Meeting
Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Laure Delaval^1,2, Maxime Samson³, Flora Schein⁴, Christian Agard⁵, Olivier Aumaître⁶, Alban Deroux⁷, Henry Dupuy⁸, Cyril Garrouste⁹, cedric landron¹⁰, Francois Maurier¹¹, Pascal Cathebras¹², Loïc Guillevin^2,13,14 and Benjamin Terrier^15,16,17, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, paris, France, ²Internal medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁴Internal medicine, University Hospital St Etienne, Saint Etienne, France, ⁵Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁶CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁷Internal Medicine, CHU de Grenoble, Grenoble, France, ⁸Department of Internal Medicine, Haut-Lévêque Hospital, Pessac, France, ⁹Nephrology, CHU, Clermont-Ferrand, France, ¹⁰service de médecine interne, CH Poitiers, CHU Poitiers, poitiers, France, ¹¹Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ¹²Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹³French Vasculitis Study Group (FVSG), Paris, France, ¹⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁵Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹⁶French Vasculitis Study Group (FVSG), paris, France, ¹⁷Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a non-necrotizing granulomatous arteritis involving large vessels, whereas antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group of necrotizing…
Abstract Number: 1763 • 2017 ACR/ARHP Annual Meeting
Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry
Caroline Morbieu, Maher Banjari, Benjamin Terrier, Pascal Cohen, Claire Le Jeunne, Luc Mouthon, Xavier Puéchal and Loïc Guillevin for the French Vasculitis Study Group, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Diagnosing ANCA-associated vasculitides (AAVs) can be challenging. Their clinical presentations are numerous and the time to diagnosis may range from days to years.1,2 The…
Abstract Number: 2935 • 2017 ACR/ARHP Annual Meeting
Nasal Microbiota in Patients with Granulomatosis with Polyangiitis Compared to Healthy Controls
Rennie L. Rhee¹, Antoine G. Sreih¹, Catherine E. Najem¹, Peter C. Grayson², Chunyu Zhao³, Kyle Bittinger³, Ronald G. Collman⁴ and Peter A. Merkel⁵, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ³Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Medicine & Microbiology, University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies have suggested a potential link between nasal microbes, in particular Staphylococcus aureus, and granulomatosis with polyangiitis (GPA; Wegener’s) but these studies relied…
Abstract Number: 814 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation and Outcome of Orbital Mass in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides
Cécile-Audrey Durel¹, Arnaud Hot², Ludovic Trefond³, Olivier Aumaître⁴, Grégory Pugnet⁵, Maxime Samson⁶, Sébastien Abad⁷, Alexandre Belot⁸, Claire Blanchard-Delaunay⁹, Pascal Cathebras¹⁰, Pascal Cohen¹¹, Fleur Cohen¹², Vincent Cottin¹³, Bruno Crestani¹⁴, Stéphanie Dumonteil¹⁵, Claire de Moreuil¹⁶, Stéphane Durupt¹⁷, Jean-Gabriel Fuzibet¹⁸, Margaux Garzaro-regard¹⁹, Nicolas Girszyn²⁰, Bertrand Godeau²¹, Eric Hachulla²², Yvan Jamilloux²³, Patrick Jego²⁴, Estibaliz Lazaro²⁵, Thomas Le Gallou²⁶, Eric Liozon²⁷, Thierry Martin²⁸, Thomas Papo²⁹, Antoinette Perlat²⁶, Pascal Pillet³⁰, Karim Sacre³¹, Pascal Sève³², Loïc Guillevin for the French Vasculitis Study Group³³ and Benjamin Terrier¹¹, ¹Internal Medicine, Hôpital Edouard Herriot, lyon, France, ²Internal Medicine, Hopital Edouard Herriot, Lyon, France, ³Internal medicine, CHU Gabriel-Montpied, clermont-ferrand, France, ⁴CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁵Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, ⁶Dijon University Hospital, Dijon, France, ⁷Internal medicine, Hôpital Avicennes, avicennes, France, ⁸Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, ⁹Internal Medicine, Centre Hospitalier, Niort, France, ¹⁰Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹¹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹²Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹³Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, ¹⁴Pneumologie A, Hôpital Bichat - Claude Bernard, Paris, France, ¹⁵Internal medicine, CHU de Limoges, Limoges, France, ¹⁶CHU de Brest, Brest, France, ¹⁷Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ¹⁸Internal medicine, Hôpital l'Archet, Nice, France, ¹⁹Internal medicine, CHU de Nice, Nice, France, ²⁰CHU de Rouen, Rouen, France, ²¹Internal medicine, Hôpital Henri-Mondor, Créteil, France, ²²CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²³Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ²⁴Medecine Interne, CHU Rennes, Rennes, France, ²⁵service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, ²⁶Internal medicine, CHU de Rennes, Rennes, France, ²⁷Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ²⁸Cnrs UPR9021, Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospital, IBMC CNRS UPR9021, Strasbourg, France, ²⁹Paris Bichat, Paris, France, ³⁰Paediatrics, Hôpital Pellegrin, University Hospital of Bordeaux, Bordeaux, France, ³¹Department of Internal Medicine, Bichat Hospital, Paris, France, ³²Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ³³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France
Background/Purpose: Orbital mass is a rare ophthalmologic manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) that remains a therapeutic challenge. This study aimed to describe…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].